IMU imugene limited

18.2%

1.3¢

this is just speculation, may not be true, assess at your own...

First 69 Last

Share
Profile

Follow
Raki

3,655 Posts.

1047

23/12/24

21:08

Post #: 77170752
Share

Originally posted by Raki: ↑

ah man looks like you are jack of all

1. The 10% premium on cash instalments applies only if Imugene chooses to pay in cash rather than shares
2. In 3 years Imugene would had made significant progress in its clinical trials this will increase the company's valuation and share price
3. The "remaining sum back" clause applies only if requested, and it’s almost certain Imugene will have the flexibility to negotiate terms or utilize alternative funding sources.
4. Dilution (if and only if it happens) is just a consequence of growth funding (every clinical stage biotech has to deal with it, nobody has unlimited funding, lets see how RAC will raise fund with just one trick dead pony) . As long as the capital raised is effectively used to advance clinical programs, the long-term value can outweigh the short-term dilution
5. Warrants are not a "gift" but an incentive for taking on risk by lending to a clinical-stage biotech
6. The funding provides a crucial runway for Imugene to achieve milestones in its Azer-Cel, onCARlytics, and VAXINIA programs
7. Clinical success could exponentially increase Imugene’s valuation, benefiting shareholders despite shortterm dilution (only if it happens)

Just consider the alternate option " Equity financing" which would had caused immediate dilution, while traditional debt financing would require regular interest payments and is rarely feasible for clinicalstage companies, this is overall a better arrangement than CR, but I always say clinical stage biotech whoever they are what ever they claim will have to do CR, not once but multiple times during the course of the journey, how they navigate this scenario makes or breaks the company, I almost gave up on PH, but this time around he has done a decent job I would say and have given LC and her team all of 2025 to achieve an outcome

Expand

this is just speculation, may not be true, assess at your own risk, as fatchoi mentioned just research "maximizing acquisition value" or "positioning for strategic acquisition" and how the leading positions are taken by company chairman leading to acquisitions.. I am being overly optimistic..

IMU Price at posting: 3.7¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

First 69 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.3¢		Change 0.002(18.2%)		Mkt cap ! $97.07M

Open	High	Low	Value	Volume
1.2¢	1.4¢	1.1¢	$625.7K	50.56M

Buyers (Bids)

No.	Vol.	Price($)
20	5795292	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.3¢	3258567	9

View Market Depth

No.	Vol.	Price($)
18	5735292	0.012
35	10497532	0.011
118	35980571	0.010
37	19431668	0.009
13	4220748	0.008

Price($)	Vol.	No.
0.013	3078567	8
0.014	10063029	39
0.015	6593187	20
0.016	6224494	27
0.017	7006978	10

Last trade - 16.10pm 27/06/2025 (20 minute delay)

IMU (ASX) Chart

this is just speculation, may not be true, assess at your own...

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

this is just speculation, may not be true, assess at your own...

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Australia’s gas crisis is here – and dying coal plants aren’t helping

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News